IFPMA Joint Guideline on Registration and Publication of Clinical Trial Results (2018.01.15)
IFPMA's Joint Guideline on Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases (dated November 18, 2008) was revised on November 10, 2009 to include at least all clinical trials involving patients. Furthermore, in this revision dated January 15, 2018, some revisions were made to the location of the publication and the content of the published information.
Please note that the place for registration of clinical trials has been changed to jRCT from September 1st, 2020.
This revised Joint Guideline has already been approved by the JAPIA, the European Federation of Pharmaceutical Manufacturers and Associations, and the US Association of Research Pharmaceutical Manufacturers and Associations, and its provisions will supersede those of the previous Joint Guideline.
Please also refer to the WHO Trial Registration Data Set (Version 1.3.1) and the August 31, 2020 MHLW Director's Notice (Registration of Clinical Trial Status).
- IFPMA Joint Guideline (Revised January 15, 2018): Japanese translation (332KB)
- IFPMA Joint Guideline (Revised 15 January 2018): Original text (474KB)
- IFPMA Joint Guideline (Revised November 10, 2009): Japanese translation (113KB)
- IFPMA Joint Guideline (Revised November 10, 2009): Original (153KB)
- IFPMA press release: Japanese translation (22KB)
- IFPMA press release: Original (43KB)